Comparative Efficacy of Rosuvastatin (Low Vs High Dose) in Lowering Low Density Lipoprotein Cholesterol in Intermediate Risk Cardiovascular Patients

Muhammad Abdul Rehman Akhtar; Tahir Siddique

doi:10.70749/ijbr.v3i3.517

Authors

Muhammad Abdul Rehman Akhtar Department of Medicine, Lahore General Hospital, Lahore, Punjab, Pakistan.
Tahir Siddique Professor of Medicine, Principal Nawaz Sharif Medical College, Gujrat, Punjab, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v3i3.517

Keywords:

Rosuvastatin, Low Density Lipoprotein – Cholesterol, Lipid Profile, Intermediate risk of Cardiovascular Disease

Abstract

Background: The enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition therapy exists as a prevalent method to control blood lipid levels. Higher statin doses demonstrate better efficacy at decreasing cardiovascular events when compared to lower dosage amounts according to the research findings. International guidelines support the use of high dose rosuvastatin yet adverse effect concerns might inhibit its actual prescription. The study evaluated how low dose rosuvastatin treatment performed against high dose rosuvastatin therapy in patients at intermediate cardiovascular risk. Methodology: The research took place within Medical OPD Lahore General Hospital stretching from July 2024 until January 2025. Researchers distributed 96 patients between Group A which received 10 mg Rosuvastatin and Group B which received 20 mg Rosuvastatin for a duration of three months. Blood tests checked serum creatine phosphokinase (CPK) and low density lipoprotein cholesterol (LDL-C) at both the study start and three months into the trial. The study evaluated effectiveness through LDL-C reductions. Results and Discussion: Group A included 37.5% male participants along with 62.5% female participants whereas Group B comprised 60.4% male participants with 39.6% female participants and their ages showed Group A averaged 49.31±10.96 years while Group B averaged 51.60±11.13 years. Group B participants demonstrated significantly lower mean LDL-C values at 172.94 ± 32.02 mg/dl when compared to Group A at 248.94 ± 53.66 mg/dl (p < 0.05). Group B reached statin efficacy at 85.4% whereas Group A achieved it only at 39.6% (p<0.05). The mean CPK levels in Groups A and B measured at 85.67 ± 19.30 and 74.65 ± 20.89 µg L− but showed statistically significant differences between these values (p < 0.05). High dose rosuvastatin provided more effective LDL-C lowering outcomes than low dose therapy for patients with intermediate cardiovascular risk.

Downloads

Download data is not yet available.

References

Collaborators, GRF. (2016). Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England), 388(10053), 1659.

Bansal, S. K. (2015). Conventional and advanced lipid parameters in premature coronary artery disease patients in India. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. https://doi.org/10.7860/jcdr/2015/14818.6844

Ma, G., & Bi, S. (2018). Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. Experimental and Therapeutic Medicine. https://doi.org/10.3892/etm.2018.6923

Ma, Q., Zhou, Y., Zhai, G., Gao, F., Zhang, L., Wang, J., Yang, Q., & Cheng, W. (2015). Meta-analysis comparing Rosuvastatin and Atorvastatin in reducing concentration of C-reactive protein in patients with hyperlipidemia. Angiology, 67(6), 526-535. https://doi.org/10.1177/0003319715599863

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., ... & Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 73(24), e285-e350. https://www.jacc.org/doi/abs/10.1016/j.jacc.2018.11.003

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., ... & Wiklund, O. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European heart journal, 41(1), 111-188. https://academic.oup.com/eurheartj/article/41/1/111/5556353

Cortese, F., Gesualdo, M., Cortese, A., Carbonara, S., Devito, F., Zito, A., Ricci, G., Scicchitano, P., & Ciccone, M. M. (2016). Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacological Research, 107, 1-18. https://doi.org/10.1016/j.phrs.2016.02.012

Lee, Y., Hong, S., Kang, W. C., Hong, B., Lee, J., Lee, J., Cho, H., Yoon, J., Lee, S., Ahn, C., Kim, J., Kim, B., Ko, Y., Choi, D., Jang, Y., & Hong, M. (2023). Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: Secondary analysis of the randomised lodestar trial. BMJ, e075837. https://doi.org/10.1136/bmj-2023-075837

Kim, H., Lee, H., Park, B., Park, S., Kim, H., Lee, S., Cho, J. H., Yoon, K., Cha, B., Kim, J. H., & Choi, I. Y. (2016). Comparative analysis of the efficacy of low- and moderate-intensity statins in Korea. Int. Journal of Clinical Pharmacology and Therapeutics, 54(11), 864-871. https://doi.org/10.5414/cp202332

Atique, M., Shehzad, N., Khan, D. M., Randhawa, F. A., Tanveer, S., Sulehria, S. B., & Athar, C. A. A. (2020). Comparative effectiveness of atorvastatin (low vs high dose) in lowering low-density lipoprotein cholesterol in intermediate risk cardiovascular patients. Pakistan Journal of Medical and Health Sciences, 14(2), 312-315.

Mostaza, J. M., & Escobar, C. (2024). Rosuvastatin-based lipid-lowering therapy for the control of LDL cholesterol in patients at high vascular risk. Journal of Clinical Medicine, 13(7), 1894. https://doi.org/10.3390/jcm13071894

Dulay, D., LaHaye, S. A., Lahey, K. A., & Day, A. G. (2009). Efficacy of alternate day versus daily dosing of rosuvastatin. Canadian Journal of Cardiology, 25(2), e28-e31. https://doi.org/10.1016/s0828-282x(09)70480-5

Olsson, A. G., McTaggart, F., & Raza, A. (2002). Rosuvastatin: A highly effective new HMG‐CoA reductase inhibitor. Cardiovascular Drug Reviews, 20(4), 303-328. https://doi.org/10.1111/j.1527-3466.2002.tb00099.x

Matalka, M. S., Ravnan, M. C., & Deedwania, P. C. (2002). Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The alternate day versus daily dosing of Atorvastatin study (ADDAS). American Heart Journal, 144(4), 674-677. https://doi.org/10.1067/mhj.2002.124399

Karlson, B. W., Palmer, M. K., Nicholls, S. J., Lundman, P., & Barter, P. J. (2015). Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the voyager meta-analysis. European Journal of Preventive Cardiology, 23(7), 744-747. https://doi.org/10.1177/2047487315598710

Li, Y., Feng, Q., Gao, W., Zhang, X., Huang, Y., & Chen, Y. (2015). The difference between Asian and western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: A meta-analysis report. BMC Cardiovascular Disorders, 15(1). https://doi.org/10.1186/1471-2261-15-6